Navigation Links
Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
Date:5/11/2010

holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over EUR 70 million in funding since inception.

More information at www.cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
2. Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
3. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
4. Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
5. BioMed Realty Trust to Webcast Company Presentation at Investor Day 2010
6. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
7. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
8. Yongye International to Present at Upcoming Investor Conferences
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
11. Brazilian Biotechnology Present at BIO 2010 Is Looking for the Worldwide Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... it expands ... line of predictive diagnostic tests, EMERYVILLE, Calif., Sept. ... acquired Lipomics Technologies of West,Sacramento, Calif. The acquisition will ... terms were not disclosed., The acquisition brings together ...
... 17 Amicus Therapeutics,(Nasdaq: FOLD ), today announced ... make a presentation at the UBS Global Life Sciences,Conference ... in New York., An audio webcast of the ... http://www.amicustherapeutics.com . Participants should allow,approximately five to ten ...
... a finding that could speed the use of sensors or ... shown that certain types of tiny organic particles, when heated ... layer of a thin polymer film and then can reversibly ... , Selectively bringing a number of particles to a surface ...
Cached Biology Technology:Tethys Bioscience Announces Acquisition of Lipomics Technologies 2Tethys Bioscience Announces Acquisition of Lipomics Technologies 3NC State engineers discover nanoparticles can break on through 2
(Date:4/23/2014)... Angeles, London (April 23, 2014). "I think one can argue ... pathwayas well as doing everything else that we canthen we ... Tom Wigley, one of the world,s foremost climate researchers, in ... , published by SAGE. Refusing to take significant action on ... eventually be needed to address the problem, Wigley explains in ...
(Date:4/22/2014)... team of Yale researchers will lead a five-year, $3 ... rain events is affecting the transport of dissolved organic ... they say could alter the chemical composition and water ... With funding from the National Science Foundation,s MacroSystems Biology ... across the watershed, which begins in Canada and runs ...
(Date:4/22/2014)... must be aware of the broad patent landscape and ... a new paper from Rice University,s Baker Institute for ... the journal Regenerative Medicine , the paper is ... in the case Association for Molecular Pathology (AMP) v. ... court case and rulings garnered discussion in the public ...
Breaking Biology News(10 mins):Is nuclear power the only way to avoid geoengineering? 2Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... uterine fibroids and significantly relieves fibroid-related symptoms in ... clinical trial reported in the June issue of ... (MRgFUS) allows radiologists to precisely target fibroids without ... immediately stops blood flow in the treated fibroid ...
... University of Toronto researchers have uncovered the basis by ... also discovered how the HIV virus works to counteract ... for pregnant women in malaria-ravished regions. , Malaria is ... than one million people every year. While the disease ...
... of smell, which in many species is critical for finding ... biologists, sharks can not use just their noses to locate ... called the lateral line. The lateral line is an organ ... and vibration in the surrounding water. According to the research ...
Cached Biology News:Focused ultrasound relieves fibroid symptoms in women 2HIV and malaria combine to adversely affect pregnant women and their infants 2New research shows sharks use their noses and bodies to locate smells 2New research shows sharks use their noses and bodies to locate smells 3
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Second Mitochondria Derived Activator of ... 20 mM HEPES, pH 7.5 AVOID FREEZE/THAW CYCLES. ... Smac/DIABLO with a carboxy terminal His•Tag ® ... E. coli . Smac/DIABLO is released along with ...
... to Decorin ( Abpromise for ... Antigen: Synthetic peptide: IGPEVPDDRDFEPS conjugated ... 6-19 of Human Decorin (fragment 36-49 ... II). Entrez GeneID: ...
Biology Products: